Document:

<PAGE>

[AMICUS THERAPEUTICS LOGO]

                                                                   EXHIBIT 10.25

                                LETTER AGREEMENT

                                    May 10, 2007

Bradley Campbell
16 Morris Drive
Princeton, NJ 08540

         RE: SEVERANCE AND CHANGE IN CONTROL AGREEMENTS

Dear Bradley:

On behalf of Amicus Therapeutics, Inc., (the "Company"), this shall serve to
confirm our agreement in the event Amicus terminates your employment without
cause or in the event of a Change in Control, Sale or Merger of the Company. By
accepting the terms of this Letter Agreement, you agree that the rights
identified in this Letter Agreement contain the complete understanding between
you and the Company related to Severance and Change in Control payments. The
April 19, 2006 Offer of Employment Letter countersigned by you ("April 19, 2006
Offer Letter," attached hereto), shall otherwise remain in full force and effect
and is hereby confirmed and ratified.

SEVERANCE PAY

In the event that your employment is terminated by the Company, except for
"Cause" as defined below, you will be eligible for a continuation of six (6)
months salary at the rate in effect at the time of termination following such
termination ("Severance Pay"). "Cause" means for any of the following reasons
(i) willful or deliberate misconduct by you that materially damages the company;
(ii) misappropriation of company assets; (iii) conviction of, or a plea of
guilty or "no contest" to, a felony or (iv) any willful disobedience of the
lawful and unambiguous instructions of the CEO of the Company; provided that the
CEO has given you written notice of such disobedience or neglect and you have
failed to cure such disobedience or neglect within a period reasonable under the
circumstances. Payment of Severance by the Company will be subject to and
contingent

<TABLE>
--------------------------------------------------------------------------------------------------------------------------
<S>                       <C>                      <C>                  <C>                     <C>
6 Cedar Brook Drive       Cranbury, NJ 08512       T: 609-662-2000      F: 609-662-2001         www.amicustherapeutics.com
</TABLE>

<PAGE>

upon your signing a waiver of rights releasing the Company from any and all
further liability or responsibility.

CHANGE IN CONTROL

If there is a Change in Control Event and you resign for Good Reason or are
terminated without Cause within six months of such Change in Control Event, then
(i) you will be eligible to receive a continuation of twelve (12) months salary,
plus payment of a bonus payment equal to the bonus earned in the preceding year
and (ii) all unvested stock options will have their remaining vesting schedule
accelerated so that all stock options are fully vested.

"Change in Control Event" means any of the following: (i) any person or entity
(except for a current stockholder) becomes the beneficial owner of greater than
50% of the then outstanding voting power of the company; (ii) a merger or
consolidation with another entity where the voting securities of the company
outstanding immediately before the transaction constitute less than a majority
of the voting power of the voting securities of the company or the surviving
entity outstanding immediately after the transaction or (iii) the sale or
disposition of all or substantially all of the company's assets. "Good Reason"
means (a) a change in your position with the company or its successors that
materially reduces your title, duties or level of responsibility; or (b) the
relocation of the company or its successor greater than 50 miles away from the
then current location of the company's principal offices.

Your right to receive accelerated vesting and salary continuation payments
pursuant to the preceding two paragraphs will be subject to and contingent upon
your signing a waiver of rights releasing the Company from any and all further
liability or responsibility.

EMPLOYMENT "AT-WILL"

It is important that you understand that the Company does not guarantee
employment for any specific period of time. You will continue to be employed on
an "at-will" basis. This means that both the Company and you will have the right
to terminate your employment at any time, for any reason, with or without prior
notice or cause. Neither you nor the Company will have an express or implied
contract limiting your right to resign or the Company's right to terminate your
employment at any time, for any reason, with or without prior notice or cause.
The "at-will" relationship will apply to you throughout your employment and
cannot be changed except by an express individual written employment agreement
signed by you and the Chief Executive Officer of the Company.

It is understood and agreed that this Letter Agreement constitutes the full
agreement between you and the Company on the subjects of Severance and Change in
Control payments. To indicate your acceptance of the terms and conditions set
forth herein, please sign one copy of this Letter Agreement in the space
indicated below and return it to the attention of Nicole Schaeffer, VP Human
Resources & Leadership Development on or before May 14, 2007. By signing below,
you agree that no other promises, express

<PAGE>

or implied, have been made to you either verbally or in writing and that no
further modifications to these terms and conditions will be effective except by
a written agreement signed by the Chief Executive Officer of the Company and you
and as authorized by the Company's Board of Directors.

                                           Very truly yours,

                                           /s/ John F. Crowley
                                           ------------------------------------
                                           John F. Crowley
                                           President and Chief Executive Officer

ACCEPTED AND AGREED:

By: /s/ Bradley Campbell                  Date:  5/10/07
    -------------------------------             -------------------------------
    Bradley Campbell

<PAGE>

[AMICUS THERAPEUTICS LOGO]

April 19, 2006

Mr. Bradley Campbell
63 Tanglewood Road
Newton, MA 02459

Dear Brad:

         On behalf of Amicus Therapeutics, inc. (the "Company"), I am pleased
to confirm our offer to you for the position of Sr. Director Business
Development reporting to me. Your start date will be mutually agreed upon but no
later then May 22, 2006.

         Prior to the commencement of your employment you will be required to
execute the Company's Confidentiality, Disclosure and Non-Competition Agreement.
A copy of this agreement is attached. In addition, as a condition of employment
Amicus requires a pre-employment drug screening.

         In consideration for all your services to be rendered to the Company
your annual base salary will be $175,000, to be paid bi-weekly in accordance
with the Company's payroll practices. Upon the completion of mutually agreed
upon individual goals and objectives as well as the achievement of specific
Company goals, you will be eligible to receive a year end bonus target of 20% of
your base salary, prorated for your date of hire, minus customary deductions.
Once you agree to join Amicus, payable with your first paycheck, you will
receive a sign on bonus of $20,000 minus customary deductions.

         Upon approval by the Board of Directors, you will receive an incentive
stock option to purchase 100,000 shares of the Company's common stock, par value
$.01 per share (the "Common Stock") pursuant to a stock option agreement in form
and substance acceptable to the Company. The options will become exercisable
over a four-year period as follows: 25% on the first anniversary of the date of
grant, and the remaining 75% in equal monthly increments thereafter. The
exercise price of the options will be the fair market value of the Company's
common stock on the date of grant. Shares issuable upon exercise of each option
will be subject to certain transfer restrictions including the right of first
refusal. Additionally, exercise of the options will be governed in accordance
with the provisions of the Company's stock option plan.

         You will be eligible to participate in the Company's health benefits
program and are eligible to participate in the Company's 401(k) as well as any
other employee benefit plan(s) that are generally made available by the Company
to its employees from time to time when and as the Company may make them
available. You will be eligible for paid Company holidays as outlined in our
Holiday Policy and you will be eligible for twenty (20) days paid vacation,
three weeks during the year and one between Christmas and New Years. Vacation
accrues on a monthly basis. Because the Company expects to

<TABLE>
--------------------------------------------------------------------------------------------------------------------------
<S>                       <C>                      <C>                  <C>                     <C>
6 Cedar Brook Drive       Cranbury, NJ 08512       7: 609-662-2000      F: 609-662-2001         www.amicustherapeutics.com
</TABLE>

<PAGE>

Bradley Campbell
April 19, 2O06
Page #2 of 3

regularly review its benefit programs to keep them up to date and competitive,
these programs are subject to periodic adjustments so that certain features may
be added, modified or deleted over time.

         Given that you currently reside over 50 miles from our location in
Cranbury NJ, you will be eligible to receive our "Homeowners Relocation
Program". The details of which are enclosed. You must complete your entire move
within 12 months of your date of hire. Should you voluntarily resign your
employment within 12 months of your date of hire, you will owe the company the
appropriate prorated portion of this relocation.

         It is important that you understand that the Company does not guarantee
employment for any specific period of time. You will be employed on an "at-will"
basis. This means that both the Company and you will have the right to terminate
your employment at any time, for any reason, with or without prior notice or
cause. Neither you nor the Company will have any express or implied contract
limiting your right to resign, or the Company's right to terminate your
employment, at any time, for any reason, with or without prior notice or cause.

         In accordance with the Immigration and Naturalization Control Act, all
new employees must provide documentation that they have the legal right to work
in the United States. A copy of Form I-9 and a list of the acceptable documents
confirming your right to work in the United States are also attached for your
convenience.

         To indicate your acceptance of our offer, please sign one copy of this
letter in the space indicated below and return it to the attention of Nicole
Schaeffer, Vice President of Human Resources & Leadership Development by April
28, 2006. Acceptance of this offer constitutes your agreement with all of the
above terms and conditions of employment with Amicus Therapeutics, Inc., and
constitutes agreement to conform to Amicus Therapeutics, Inc. rules and
procedures. By signing below, you agree that no other promises, express or
implied, have been made to you either verbally or in writing and that no further
modifications to these terms and conditions will be effective except by a
written agreement signed by the Chief Executive Officer of the Company and you.

         The formality of this letter notwithstanding, I extend my personal
best wishes and sincere pleasure that you are joining our team. I look forward
to working with you.

Sincerely,

/s/ Greg Licholai
--------------------------------------------
Dr. Greg Licholai
VP Medical Affairs and Corporate Development

<PAGE>

Bradley Campbell
April 19, 2006
Page #3 of 3

I accept the offer of employment under the terms and conditions stated above. No
other promises, express or implied, have been made to me either verbally or in
writing.

By: /s/ Bradley Campbell                  Date:  4/26/06
    -------------------------------             -------------------------------
    Bradley CampbellEX-10.1

 

Exhibit 10.1

FOURTH AMENDMENT TO CREDIT AGREEMENT

     THIS FOURTH AMENDMENT TO CREDIT AGREEMENT dated as of May 15, 2007 (this “Amendment”)
by and among THE BISYS GROUP, INC., a Delaware corporation (the “Borrower”), the several
banks and other financial institutions from time to time party hereto (the “Lenders”), and
SUNTRUST BANK, in its capacity as Administrative Agent for the Lenders (the “Administrative
Agent”).

     WHEREAS, the Borrower, the Lenders party thereto and the Administrative Agent are parties to
that certain Credit Agreement dated as of January 3, 2006, as amended by that certain First
Amendment to Credit Agreement dated as of August 31, 2006, as further amended by that certain
Second Amendment to Credit Agreement dated as of November 15, 2006, and as further amended by that
certain Third Amendment to Credit Agreement dated as of December 20, 2006 (as so amended, the
“Credit Agreement”);

     WHEREAS, the Borrower desires to declare and pay a one-time dividend out of surplus in an
amount up to, but not to exceed, $50,000,000, and has requested that the Lenders permit the payment
of such dividend under the Credit Agreement;

     WHEREAS, the Borrower, the Lenders party hereto and the Administrative Agent desire to amend
the Credit Agreement in order to permit the payment of such dividend on the terms and conditions
contained herein;

     NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged by the parties hereto, the parties hereto hereby agree as follows:

     Section 1. Amendment to Credit Agreement.

     (a) The Credit Agreement is hereby amended by deleting the word “and” at the end of clause (d)
in Section 7.8 of the Credit Agreement, by deleting the “.” at the end of clause (e) of such
Section and by replacing such “.” with the following:

     “; and

     (f) the Borrower may declare and make a one-time dividend out of then available surplus
to the holders of the Borrower’s common stock (the “Special Dividend”) in an amount not to
exceed $50,000,000; provided, that (i) the Special Dividend is permitted under that
certain Agreement and Plan of Merger dated as of May 1, 2007 (the “Merger Agreement”) among
Citibank, N.A. (the “Buyer”), Buckeye Acquisition Sub, Inc. and the Borrower; (ii) each of
the Buyer and/or the Borrower, as the case may be, shall have obtained (a) all governmental,
shareholder and third party consents and approvals required as conditions precedent to
consummation of Merger (as defined in the Merger Agreement) pursuant to the Merger Agreement
and (b) if applicable, all shareholder and third party consents and approvals necessary in
connection with the declaration and payment of the Special Dividend and the incurrence

 

 

of Loans for the funding of the Special Dividend; and (iii) the payment of the Special
Dividend is conditioned upon consummation of the Merger (as defined in the Merger
Agreement).”

     Section 2. Effectiveness of Amendment. The effectiveness of this Amendment is
subject to the truth and accuracy of the representations set forth in Section 3 below and receipt
by the Administrative Agent of counterparts of this Amendment duly executed by the Borrower, each
Subsidiary Guarantor, the Administrative Agent and the Required Lenders.

     Section 3. Representations of Borrower. The Borrower represents and warrants to the
Administrative Agent and the Lenders that:

     (a) Corporate Power and Authority. The Borrower has the corporate power and authority
to execute, deliver and perform the terms and provisions of this Amendment, and has taken all
necessary corporate action to authorize the execution, delivery and performance by it of this
Amendment. The Borrower has duly executed and delivered this Amendment, and this Amendment
constitutes its legal, valid and binding obligation enforceable in accordance with its terms,
except to the extent that the enforceability thereof may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium or other similar laws generally affecting creditors’ rights
and by equitable principles (regardless of whether enforcement is sought in equity or at law).

     (b) No Violation. Neither the execution, delivery or performance by the Borrower of
this Amendment and the Credit Agreement, as amended hereby, nor compliance by it with the terms and
provisions hereof and thereof, nor the declaration and payment of the Special Dividend, (i) will
contravene any provision of any law, statute, rule or regulation or any order, writ, injunction or
decree of any court or Governmental Authority, (ii) will conflict with or result in any breach of
any of the terms, covenants, conditions or provisions of, or constitute a default under, or result
in the creation or imposition of (or the obligation to create or impose) any Lien upon any of the
property or assets of the Borrower pursuant to the terms of any material indenture, mortgage, deed
of trust, credit agreement or loan agreement, or any other material agreement, contract or
instrument, to which the Borrower is a party or by which it or any of its property or assets is
bound or to which it may be subject or (iii) will violate any provision of the certificate or
articles of incorporation or by-laws (or equivalent organizational documents) of the Borrower.

     (c) Governmental Approvals. No order, consent, approval, license, authorization or
validation of, or filing, recording or registration with (except for those that have otherwise been
obtained or made on or prior to the date of the effectiveness of this Amendment and which remain in
full force and effect on such date) or exemption by, any Governmental Authority, is required to
authorize, or is required in connection with, (i) the execution, delivery and performance of this
Amendment by the Borrower, (ii) the legality, validity, binding effect or enforceability of this
Amendment, and the Credit Agreement, as amended hereby, against the Borrower or (iii) the
declaration and payment of the Special Dividend.

- 2 -

 

     (d) No Default. No Default or Event of Default now exists or will exist immediately
after giving effect to this Amendment and the payment of the Special Dividend.

     (e) Reaffirmation of Representations. The Borrower hereby repeats and reaffirms all
representations and warranties made by it to the Administrative Agent and the Lenders in the Credit
Agreement and the other Loan Documents to which it is a party on and as of the date hereof (and
after giving effect to this Amendment) with the same force and effect as if such representations
and warranties were set forth in this Amendment in full (except to the extent of changes resulting
from transactions contemplated or permitted by the Credit Agreement and the other Loan Documents
and changes occurring in the ordinary course of business that singly or in the aggregate are not
materially adverse, and to the extent that such representations and warranties relate expressly to
an earlier date).

     Section 4. Amendment as a Loan Document. Each reference in the Credit Agreement or
in any of the other Loan Documents to “Loan Documents” shall be deemed to include a reference to
this Amendment, and this Amendment shall be a Loan Document for all purposes under the Loan
Documents.

     Section 5. References to the Credit Agreement. Each reference to the Credit
Agreement in any of the Loan Documents (including the Credit Agreement) shall be deemed to be a
reference to the Credit Agreement, as amended by this Amendment.

     Section 6. Acknowledgment of Request for Extension of Maturity Date. The
Administrative Agent and the Lenders hereby acknowledge that, in accordance with Section 2.5 of the
Credit Agreement, the Borrower has requested an extension of the Maturity Date to December 31,
2007. Subject to the satisfaction of the conditions set forth clauses (a) and (b) of Section 2.5
of the Credit Agreement, the Maturity Date shall be extended to December 31, 2007 without any
further action on the part of the Borrower.

     Section 7. Benefits. This Amendment shall be binding upon and shall inure to the
benefit of the parties hereto and their respective permitted successors and assigns.

     Section 8. Expenses. The Borrower agrees to reimburse the Lenders and the
Administrative Agent on demand for all reasonable costs and expenses (including, without
limitation, attorneys’ fees) incurred by such parties in negotiating, documenting and consummating
this Amendment, the other documents referred to herein, and the transactions contemplated hereby
and thereby.

     Section 9. GOVERNING LAW. THIS AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE
PARTIES HEREUNDER SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF
NEW YORK.

     Section 10. Effect/No Novation. Except as expressly herein amended, the terms and
conditions of the Credit Agreement and the other Loan Documents shall remain in full force and

- 3 -

 

effect. Neither this Amendment nor any of the transactions contemplated hereby shall be deemed to
be a novation of any of the Obligations.

     Section 11. Counterparts. This Amendment may be executed in any number of
counterparts, each of which shall be deemed to be an original and shall be binding upon all
parties, their successors and assigns.

     Section 12. Definitions. All capitalized terms not otherwise defined herein are used
herein with the respective definitions given them in the Credit Agreement.

[Signatures on Following Pages]

- 4 -

 

     IN WITNESS WHEREOF, the parties hereto have caused this Fourth Amendment to Credit
Agreement to be executed as of the date first above written.

	 	 	 	 	 
	 	BORROWER:

THE BISYS GROUP, INC.

 	 
	 	By:  	/s/ Bruce Dalziel
 	 
	 	 	Name:  	Bruce Dalziel 	 
	 	 	Title:  	Chief Financial Officer 	 
	 

[Signatures Continued on Following Page]

- 5 -

 

[Signature Page to Fourth Amendment to Credit Agreement

dated as of May 15, 2007 with THE BISYS GROUP, INC.]

	 	 	 	 	 	 	 
	 	 	ADMINISTRATIVE AGENT AND LENDERS:
	 
	 	 	 	 	 	 
	 	 	SUNTRUST BANK, Individually and as Administrative
Agent
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Tim O’Leary	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: Timothy M. O’Leary	 	 
	 

	 	 	 	Title: Managing Director	 	 

[Signatures Continued on Following Page]

 

 

[Signature Page to Fourth Amendment to Credit Agreement

dated as of May 15, 2007 with THE BISYS GROUP, INC.]

The following hereby execute this Fourth Amendment to Credit Agreement to indicate their
consent thereto and agreement therewith and to acknowledge that the making of this Fourth Amendment
to Credit Agreement shall not terminate, limit or otherwise adversely affect any of their
respective obligations to the Administrative Agent, the Issuing Bank and the Lenders under the Loan
Documents. Further, the following hereby reaffirm their respective continuing obligations as a
guarantor of the Guaranteed Obligations (as defined in the Guarantee Agreement) under the Guarantee
Agreement and their respective obligations under each of the other Loan Documents to which they are
a party.

	 	 	 	 	 	 	 
	 	 	ASCENSUS INSURANCE SERVICES, INC.
	 
	 	 	 	 	 	 
	 	 	BISYS COMMERCIAL INSURANCE SERVICES, INC.
	 
	 	 	 	 	 	 
	 	 	BISYS FINANCING COMPANY
	 
	 	 	 	 	 	 
	 	 	BISYS FUND SERVICES OHIO, INC.
	 
	 	 	 	 	 	 
	 	 	BISYS INSURANCE SERVICE HOLDING CORP.
	 
	 	 	 	 	 	 
	 	 	BISYS INSURANCE SERVICES, INC.
	 
	 	 	 	 	 	 
	 	 	BISYS MANAGEMENT COMPANY
	 
	 	 	 	 	 	 
	 	 	BISYS PRIVATE EQUITY SERVICES, INC.
	 
	 	 	 	 	 	 
	 	 	BISYS RETIREMENT SERVICES, INC.
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Steven Kyono	 	 
	 

	 	 	 	 	 	 
	 

	 	Name:
	 	Steven Kyono	 	 
	 

	 	Title:
	 	Executive Vice President of each of
the above-listed Guarantors	 	 

[Signatures End]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}]]